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Abstract 
Three patients from a large consanguineous family, and one unrelated patient had exercise intolerance since early childhood and 
improved by supplementation with a high dosage of riboflavin. This was confirmed by higher endurance power in exercise testing. 
Riboflavin had been given because complex I, which contains riboflavin in FMN, one of its prosthetic groups, had a very low activity in 
muscle. Histochemistry showed an increase of subsarcolemmal mitochondria. The low complex I activity contrasted with an increase of 
the activities of succinate dehydrogenase, uccinate-cytochrome c oxidoreductase and cytochrome c oxidase. Isolated mitochondria from 
these muscle specimens proved deficient in oxidizing pyruvate plus malate and other NAD +-linked substrates, but oxidized succinate and 
ascorbate at equal or higher levels than controls. Two years later a second biopsy was taken in one of the patients, and the activity of 
complex I had increased from 16% to 47% of the average activity in controls. In the four biopsies, cytochrome c oxidase activity 
correlated negatively with age. We suspect hat this is due to reactive oxygen species generated by the proliferating mitochondria and 
peroxidizing unsaturated fatty acids of cardiolipin. Three of the four patients had low blood carnitine, and all were found to have 
hypocarnitinemic family members. 
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1. Introduction 
The large number of reports about mitochondrial DNA 
mutations, contrasts with the modest number of those 
about therapy of defects in oxidative phosphorylation [1-  
30]. This is surprising, because there are many good 
reasons to study the therapy of these patients. The number 
of patients with mitochondrial problems is steadily increas- 
ing, and effective treatment should be a constant concern 
to scientists. The insight into the pathophysiology of the 
diseases involving oxidative phosphorylation is not at all 
in pace with the knowledge of the molecular biology. The 
best proof of understanding the mechanisms of their patho- 
physiology is to alleviate the condition. The reasons why 
treatment of the patients may be successful are many fold, 
such as the existence of vitamin-responsive inborn errors 
of metabolism, the high residual activity often encountered 
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in these mitochondrial defects, the plasticity of the mito- 
chondria, the fact that a small increase in activity of a 
deficient enzyme may have a high effect on the metabolic 
flux, the availability of many safe drugs, carnitine (re- 
cently reviewed in Ref. [6]) and vitamins, the efficacy of 
which can be tested by exercise tests, and finally the fact 
that searching a cure is important for patients (family), 
clinicians and their relationship. 
It is true that therapy in defects of oxidative phospho- 
rylation is often disappointing, but an increasing amount of 
reports on single patients, indicates that therapeutic at- 
tempts could be successful. Table 1 summarizes reports of 
successful therapy in primary oxidative phosphorylation 
defects. Criticists could argue that these 'anecdotical' re- 
ports prove nothing, since the natural history of these 
diseases is not known well enough and the improvement 
cannot be excluded to be part of the course of the disease. 
Another view is that therapeutic successes are more readily 
published than failures, and less frequently as suggested by 
literature [3]. 
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It is the purpose of this paper to report the investiga- 
tions in four patients with riboflavin-responsive complex I 
deficiency. 
2. Materials and methods 
2.1. Clinical findings 
Two girls CV (11 years), CB (15 years), a man JJ (22 
years) and his sister MJ (24 years) suffered from easy 
fatiguability and exercise intolerance since early child- 
hood. On routine examination o muscle weakness was 
found. They had lactic acidemia of 7.8, 6.5, 2.7 and 3.0 
mmol/1 (controls up to 1.9 mmol/1). Serum creatine 
kinase was slightly elevated in the man (177 U/ l ,  controls 
up to 110 U/I), and normal in the others. Cardiac, pul- 
monary, visual and renal dysfunction were excluded in all 
patients. 
CV complained of pain in her legs after walking 100- 
200 m, and had dyspnoea nd palpitations on exercise. 
CB was completely exhausted and nauseated after 5 km 
of cycling, the distance to school. She failed to cycle this 
distance with adverse wind. She had one stroke-like pisode 
at the age of 13 years, with left-sided weakness. She was 
short for her age. 
JJ had to cycle 15 km to school, and had experienced 
the same problems as CB. After exercising, he experienced 
pain at the level of the stomach. At the age of 23 years, he 
had a brief episode of blurred vision, and a headache 
which disappeared after 2 days. He had no migraines. His 
work required strenuous exercise, but he had less en- 
durance power than his colleagues. 
MJ had the same problems as her brother, and often 
went to school (15 km) by bus. She had not experienced a 
stroke-like pisode. She gave birth to a son, and during the 
pregnancy she felt very tired from at the beginning of each 
day. 
The other family members could exercise normally and 
had no problems with cycling, including the mother of JJ 
and MJ. Her plasma lactate was 0.3 mmol/1. 
An open muscle biopsy was taken from CB, CV and J J, 
respectively. After the finding of a complex I deficiency in 
biopsied muscle a therapeutic trial was started. Per day, 
and per os, CV received a mixture of vitamins (biotin 20 
mg, riboflavin 100 mg, nicotinamide 200 mg), amino acids 
for the production of Krebs cycle intermediates (L-valine 1 
g, L-isoleucine 1 g, L-aspartate 1 g) and DL-carnitine-HC1 
(2 g). CB received 10-100 mg riboflavin, JJ and MJ 100 
mg riboflavin. Directly after therapy increased endurance 
power was reported by the patients and exercise related 
nausea nd pains disappeared. CB had no more stroke-like 
episodes. After 1-2 years of riboflavin therapy, their rest- 
ing lactate decreased and the exercise tolerance assessed 
by ergometry increased. Later on, no further improvement 
was observed. CV stopped therapy and reinstitution of 
Table 1 
Successful therapy in defects of oxidative phosphorylation 
Defect(s) Therapy 1 st author, year, Ref. 
Kearns-Sayre Thiamine Lou, 1981 [7] 
Complex I Riboflavin Arts, 1983 [8] 
Scholte, 1987 [9] 
Griebel, 1990 [10] 
Bernsen, 1991 [11] 
Bernsen, 1993 [12] 
Bakker, 1994 [13] 
Complex III Menadione + ascorbate Argov, 1986 [ 14] 
Kearns-Sayre CoQ Ogasahara, 1985 [ 15] 
Ogasahara, 1986 [16] 
Cytochrome c I Ascorbate Przyrembel, 1987 [3] 
MELAS CoQ Goda, 1987 [ 17] 
Yamamoto, 1987 [18] 
Ihara, 1989 [19] 
Complex I Succinate Kobayashi, 1987 [20] 
Complex I with low K m for NADH Nicotinamide Scholte, 1987 [9] 
Mitochondrial myopathies CoQ Bresolin, 1988 [21 ] 
Bresolin, 1990 [22] 
Complex IV CoQ Nishikawa, 1989 [23] 
Complex I Menadione + succinate Wijburg, 1989 [24] 
Kearns-Sayre & pyruvate dehydrogenase Thiamin + riboflavin Scholte, 1991 [25] 
Complex I and IV CoQ Bendahan, 1992 [26] 
Adenine nucleotide translocator Vitamin E Bakker, 1993bc [27,28] 
Zierz and coworkers [29] showed that CoQ supplementation did not raise the CoQ concentration i  muscle. The key question is if CoQ supplementation 
increases its level in the respiratory chain. Ernster and coworkers howed that this is not the case in rats (this volume). Folkerts and coworkers claimed that 
it is the case in humans (this volume). Matthews et al. [30] demonstrated in 16 patients with a variety of mitochondrial diseases that CoQ, menadione, 
ascorbate, thiamine and niacin were ineffective in treatment. See also Martens et al. in this volume. 
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Fig. 1. Left Gomori trichrome staining, right succinate-tetrazolium oxidoreductase. Patient CV: la, lb. Patient CB: lc, ld. Patient JJi (first biopsy): le, If. 
Patient JJ2 (second biopsy): lg, lh. 
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daily riboflavin (300 mg) plus L-carnitine (2 g) decreased 
resting plasma lactate and increased the creatine phosphate 
resynthesis rate after exercise, assessed in the living mus- 
cle by 31p magnetic resonance spectroscopy [13]. 
The patients were diagnosed in 1985 and 1986 and 
treated since then. In 1992, blood was taken from the 
sibling and parents of CB and JJ for future investigation of 
nuclear DNA in Nijmegen, and for the determination of
camitine. The family members recalled the favourable 
therapeutic hanges to the riboflavin therapy in the pa- 
tients. 
Preliminary biochemical results of patient CB were 
presented in [9], and a report about patient CV appeared 
recently [13]. 
2.2. Muscle biopsy, morphological nd mitochondrial DNA 
investigations 
CV, CB and JJ were biopsied by the open procedure 
under local analgesia from the M. quadriceps. Part of the 
muscle was immediately immersed in ice-cold medium for 
the isolation of mitochondria. The remainder was snap 
frozen for later routine histology and histochemistry, ho- 
mogenate biochemistry and screening of mitochondrial 
DNA mutations. A piece of muscle was taken out by a 
special forceps and fixed in glutaraldehyde for electron 
microscopy. JJ was again biopsied 2 years later, after 
therapy with riboflavin from the M. extensor carpi radi- 
alis. 
Dr. B.A. van Oost and coworkers creened the muscle 
samples for deletions and the 'common' MERRF and 
MELAS mutations, but these were not found. 
2.3. Isolation of and assays on muscle mitochondria 
Muscle mitochondria were isolated according to 
Bookelman et al. [31]. The assays were performed as in 
earlier work [9,32]. For the calculation of oxygen uptake, 
which was expressed in nmol 02 per min, HRS learned 
during a workshop in Innsbruck from Dr. E. Gnaiger and 
Dr. W.S. Kunz, that in previous work we had overesti- 
mated the amount of oxygen in the oxymetric vessel. We 
therefore recalculated oxygen uptake rates and P /O  ratios 
assuming that the concentration of 0 2 in our ions and 
albumin containing medium at 25°C was 230 /xM [33,34] 
instead of 267/~M. 
2.4. Preparation of and assays on muscle homogenate 
This was performed as described before [9,32]. Cy- 
tochrome c oxidase was assayed according to Cooperstein 
and Lazarov [35], but with a potassium phosphate buffer 
concentration of 0.1 M Pi, and horse heart cytochrome c 
(Fe z+) without dithionite. 
Fig. 2. Stainings ee Fig. 1. Patient AD, with complex I deficiency and ragged-red fibres at the age of 15 y: 2a, 2b (patient 1 in Ref. [9]), and at the age of 
19 y: 2c, 2d. His mother had the same condition, but a mutation in mitochondrial DNA had not been found (Dr. B.A. van Oost and coworkers). 
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2.5. Determination of exercise tolerance by bicycle ergom- 
et~. [36,37] 
The exercise protocol was as follows. Metabolic, venti- 
latory and circulatory variables were measured in the last 
min of 4 min periods with constant workload, increasing 
stepwise every 4 rain, till the heart rate became higher than 
180 beats per min, or till exhaustion. The ergometer- 
workload was largely independent of pedalling frequency 
(Hyperbolic type, Lode, Groningen, The Netherlands) and 
ventilation was measured in the expiratory line with a Lilly 
type pneumotachometer, which was linear up to 750 
l.min J (Jaeger, Wiirzburg, Germany). Volume was ob- 
tained as integrated flow. Volume calibration was done 
with a 1 1 syringe and correction factors were applied for 
calculation of the volume at the appropriate conditions of 
temperature and humidity. The patients breathed via a low 
resistance two way valve (Jaeger, Wiirzburg) into a mixing 
box of 3 1, from which mixed expired gases were sampled. 
CO 2 was measured with an infrared-analyzer (Jaeger, 
Wtirzburg) and 02 with a paramagnetic analyzer (Taylor 
Servomex, OA 150, adapted for our purpose by Mijnhardt, 
Odijk, The Netherlands). The oxygen uptake (V o) was 
estimated from the mixed expired O 2 concentration and 
ventilation (Ve). Lactate was determined at rest and maxi- 
mal exercise in venous blood from a non-exercising mus- 
cle (brachial vein). At 4 occasions, a screening protocol 
was used in which no ventilatory and metabolic data were 
obtained, and maximal exercise capacity was determined 
by the maximal workload, heart rate and lactate levels. 
3. Results 
3.1. The morphology of muscle and muscle mitochondria 
The fibre typing by Ca2+-ATPase, and the distribution 
and amount of glycogen were as in controls. The amount 
of fat droplets was slightly increased. The number of 
subsarcolemmal mitochondria was strongly increased, as 
shown with Gomori's trichrome stain (Fig. 1, left), and 
with succinate-tetrazolium oxidoreductase (Fig. 1, right). 
The sarcoplasm was not fragmented and the fibres had no 
ragged appearance. The same staining methods were per- 
formed in a boy with ragged-red fibres and complex I 
deficiency at ages 15 and 19 years (Fig. 2). The morpho- 
logical condition in the patients of Fig. 1 can be described 
as excessively red, but not ragged. Morgan-Hughes de- 
Table 2 
Activities of isolated muscle mitochondria * 
CV CB JJi Controls n ~ 
O2-uptake rates (nmol 02 ) 
Pyruvate + malate + ADP 4 
Glutamate + malate + ADP 5 
Palmitoylcarnitine + malate + ADP 6 
Succinate + rotenone + ADP 50 
Ascorbate + TMPD b + ADP 142 
Ascorbate + TMPD + DNP c 198 
RCI d Pyruvate 0.7 
RCI Ascorbate 1.4 
P /O  ~ Pyruvate 1.3 
P /O  Ascorbate 0.7 
Mg 2 +_ATPase (nmol ATP) 4 I 
+ uncoupler 1078 
Radiopalmitate oxidation (nmol palmitate) 
+ 1 mM KCN + 0.1 mM CoA 0.2 
+ 0.5 mM L-carnitine + 0.1 mM CoA 1.2 
+ 5 mM L-carnitine + 1 mM CoA l. l  
Malonyl-CoA decarboxylase 
(nmol) 0.1 
+ detergent 2.6 
Succinate dehydrogenase 
(nmol INT +) i 55 
Practical yield 
(rag protein/g wet wt) 17 
Recovery (%) 27 
8 10 35(17-50) 22 
8 8 35(19-73) 22 
9 9 29(17-48) 22 
71 82 45(27-84) 22 
301 271 148(99-202) 22 
349 277 173(100-224) 9 
0.9 1.0 2.5(1.5-4.6) 22 
1.9 2.0 1.7(1.3-2.8) 22 
2.3 3.4 2.0(1.5-2.3) 5 
1.2 0.6 0.5(0.3-1.0) 7 
27 30 44(0-175) 19 
885 1135 603(174-1003) 19 
0.5 0.2 0.2(0.1-0.4) 12 
1.4 1.6 1.7(1.1-2.5) 14 
1.8 2.7 1.9( 1.1-2.3 ) 9 
0.2 0.1(0.0-0.8) 9 
1.9 1.4(0.9-3.1) 9 
54 62 27(12-57) 21 
10 4.6 4.7(1.0-1 t) 22 
16 14 16(4.9-45) 21 
The activities were expressed in indicated amounts of substrate.min- I.(mg protein)- t. 
n = number of independent controls. 
h TMPD = tetramethyl-p-phenylenediamine us d in a concentration of 0.6 mmol/I. 
" DNP = 2,4-dinitrophenol. 
d RCI = stimulation of oxygen uptake rate by ADP. 
P /O  = mol approx. P produced/0.5 mol 02 consumed. 
f INT* = p-iodotetrazolium. 
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scribed this condition as: 'Rim(med) with red staining 
granular material, but without a ragged-red appearance' 
[38]. The staining of type I and also of type II fibres by 
succinate-tetrazolium oxidoreductase, was more intense 
than in controls, and the difference between the fibre types 
was less pronounced than in controls. In patient CV it was 
no longer possible to distinguish the fibre types in this 
stain. Cytochrome c oxidase staining showed a better 
difference between the fibre types in patient CV, but the 
Cae+-ATPases gave a better contrast. This was also true 
for patients CB and JJ. There were no cytochrome c 
oxidase negative fibres. A second biopsy from JJ after 
riboflavin treatment was similar to that before treatment. 
The fact that the muscle fibres were larger after therapy 
could be related to the other muscle (quadriceps in Figs. 
1 e, I f vs. extensor carpi in Figs. I g, I h). 
Electron microscopy confirmed the subsarcolemmal 
mitochondrial accumulation. They were abnormal in size 
distribution. The larger mitochondria showed an abnormal 
organization of the cristae and an increase in dense bodies. 
Crystalline inclusions were not found. 
3.2. Biochemist~. of  muscle mitochondria nd muscle ho- 
mogenate 
The oxygen uptake rates with the NAD+-linked sub- 
strates were decreased to 11-31% of the average rates in 
controls (Table 2). This contrasted with the normal oxida- 
tion of succinate in the presence of rotenone and the 
normal (CV) to highly increased oxidation (CB, J J) of 
ascorbate plus TMPD. Uncoupler increased this oxidation 
by 39% (CV), 16% (CB) and 2% (J J), which is in the 
range of controls (1-51%). The RCIs with pyruvate plus 
malate were low (0.7-1.0), which is a common finding 
with poorly oxidized substrates. The quality of the cou- 
pling between oxidation and phosphorylation was demon- 
strated by the good RCIs with ascorbate plus TMPD. The 
yields of oxidative phosphorylation, as expressed by the 
P /O  ratios were also good. The integrity of the mito- 
chondria was further demonstrated by the low Mg 2+- 
ATPase activity of the mitochondria, and the impressive 
stimulation of this activity by uncoupler (26-, 33- and 
39-fold, which is much higher than in the average control). 
Palmitate oxidation, measured in the presence of 
cyanide, reflects the peroxisomal /3-oxidation. With low 
(0.5 mM) carnitine, also the mitochondrial contribution 
was measured, which was in the control range. An expla- 
nation for the discrepancy with the low oxidation of 
palmitoylcarnitine plus malate, is that the latter reaction 
uses much more oxygen than the former, where acylcarni- 
tine and not CO 2 is an important product [39]. High (5 
mM) carnitine did not stimulate the /3-oxidation in CV 
further. In CB there was a clear stimulation, and the 
greatest stimulation was found in JJ. It is likely that a high 
stimulation of the mitochondrial /3-oxidation by 5 mM 
camitine reflects a high intramitochondrial acy l -CoA/CoA 
ratio [40]. 
In addition to the uncoupler-stimulation f the Mg 2+- 
ATPase, the high stimulation by detergent of the mito- 
chondrial matrix enzyme malonyl-CoA decarboxylase in
patients CV and J J, indicates the integrity of the mitochon- 
drial inner membranes. Like citrate synthetase, this matrix 
enzyme reacts with a substrate, which cannot pass the 
intact inner membrane. The mitochondrial yield in the 
patients decreased with age (17, 10 and 4.6 mg protein/g 
muscle). This is not the case in controls. The recovery of 
the isolation was 14-27%. Isolation of mitochondria l- 
ways imply the danger of selection. The isolated mito- 
chondria, with their inability of oxidize NAD+-linked sub- 
strates, may not represent the properties of the not isolated 
mitochondria. For this reason, it is important not only to 
study isolated mitochondria, but also mitochondrial activi- 
ties in the homogenate [41]. We investigated a so-called 
'total' homogenate, which was not centrifugated, to avoid 
selection [42]. The results are summarized in Table 3. The 
activity of complex I, measured as rotenone-sensitive 
NADH oxidase, was decreased to 9% (CV), 5% (CB) and 
16% (JJj). After two years of riboflavin therapy the latter 
activity bad increased to 47% (JJ2), an activity which is in 
the (lower) range of controls. The activity of succinate 
Table 3 
Mitochondrial enzymes, creatine kinase, and total carnitine and protein in muscle homogenates 
Patients CV CB JJI JJ~ Controls n 
Age (years) 11.9 15.1 22.6 24.7 
Complex I (/~mol NADH) 0.33 0.18 0.58 1.71 
Succinate dehydrogenase (/zmol INT + ) 3.38 3.44 2.00 3.15 
Complex II + III (/~mol cytochrome c) 11.1 14.8 11.3 13.7 
Complex IV (lst order ate constant k) 413 305 257 163 
CPT I (nmol _-carnitine) 138 121 119 89 
CPT II (nmol L-carnitine) 162 200 122 126 
Creatine kinase (p~mol creatine) 425 335 388 379 
Total carnitine (/xmol per g wet wt) 2.49 3.25 2.58 2.57 
Protein (mg per g wet wt) 187 175 195 186 
3.7(1.6-7.3) 45 
0.72(0.19-1.64) 58 
5.2(1.6-12.5) 54 
95(45-161 ) 49 
77(43-165) 55 
96(57-174) 57 
307(83-430) 50 
3.96(2.57-5.73) 59 
174(77-263) 53 
The activities are expressed in amount of substrate.min- t .(g wet weight)- J.
CPT = carnitine palmitoyltransferase. 
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dehydrogenase was increased to 278-478% of the average 
activity in controls, complex II + I I I  to 213-285%, com- 
plex IV to 270-435%, CPT I to 155-179%, CPT II to 
127-208% and creatine kinase, in contrast o the preceding 
mitochondrial activities mainly residing in the cytosol, to 
109-138%. The last 3 enzyme activities were in, or closer 
to, the range of controls than the activities of the terminal 
respiratory chain. Carnitine had about the same level as in 
the lowest control in patients CV and J J, and was normal 
in patient CB. 
3.3. Exercise testing 
The efficacy of the riboflavin treatment was assessed by 
bicycle ergometry of patients CB, JJ and MJ (Table 4) and 
3~p magnetic resonance spectroscopy of patient CV [13]. 
Before treatment CB could exercise 4 min 30 Watts and 
was exhausted at a heart rate of 147 beats/min. Her blood 
lactate before the test was 6.5 mM and increased to 12.8 
mM at the end of the test. After receiving 10 mg riboflavin 
per day she could perform 4 min 30 Watts plus 2 min 60 
Watts at a heart rate of 183 bpm, and lactate rose from 3.7 
to 10.7 mM. After another year on 100 mg riboflavin her 
maximal workload had increased to 4 min 30 Watts, 4 min 
60 Watts plus 4 min 90 Watts, her heart rate was 186 bpm 
and lactate rose from 2.5 mM to 14.2 mM. The amount of 
work performed per amount of oxygen consumed and per 
amount of lactate produced increased considerably. No 
more improvement was found in later studies. JJ showed 
the same, but reached already a heart rate of 180 bpm 
before treatment. By his daily physical labour he was 
obviously better trained and could perform more work 
before therapy than CB. MJ has not been tested before 
riboflavin treatment. After therapy, two measurements 
yielded about the same results, but lactate at rest was 
higher the second time. It is striking that the maximal 
workloads after therapy were so different in the three 
patients. 
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Fig. 3. The pedigree of families B and J. This pedigree was recontructed 
with the help of the archives of the Genealogical Society of Utah in Salt 
Lake City, USA. 
3.4. Family relationship 
Geneological research revealed that CB and JJ were 
related (Fig. 3). This had been expected because of the 
great clinical similarity between the patients, and the fact 
that they lived on the same small Dutch island, which 
could only be reached by boat until the Delta works were 
constructed after the Dutch flood disaster of 1953. The 
implication of this complicated consanguineous pedigree is 
that the heredity of the condition is autosomal recessive. 
CV comes from another part of the country, and a relation 
between her family and that of CB and JJ could not been 
found. From all available vidence, it is likely that CV has 
the same condition as CB, JJ and MJ. All other patients we 
studied with complex I deficiency had a decreased or 
normal cytochrome c oxidase activity, and ragged-red or 
normal fibres. 
3.5. Plasma carnitine 
Free and total carnitine in plasma from the families, 
revealed that the patients CV, JJ and MJ were hypocar- 
Table 4 
Determination f exercise tolerance by cycle ergometry 
Patient Age R ibo f lav in  Workload * V E * V o * HR * LA * * LA * 
years mg/day min Watts l/min nmol/min /min mmol/l 
CB 15 0 4 30 37 34 147 6.5 12.8 
CB 16 10 2 60 38 31 183 3.7 10.7 
CB 17 100 1 90 51 41 186 2.5 14.2 
CB 18 25 1 90 183 3.8 15.5 
CB 19 25 1 90 50 44 183 3.8 12.8 
JJ 22 0 4 60 64 48 180 8.8 14.3 
JJ 23 100 1 120 88 76 189 6.2 16.3 
JJ 24 100 4 90 71 75 186 4.9 15.5 
JJ 26 100 1 120 190 6.9 14.1 
MJ 26 100 2 90 198 4.7 14.8 
MJ 29 100 2 90 196 8.2 18.3 
The workload was stepwise increased from 4 min 30 Watts, 4 min 60 Watts, 4 min 90 Watts etc. till the heart rate became higher than 180 beats per min, 
or till exhaustion. 
* At maximal exercise. * * Before exercise. VE = ventilation. V o = oxygen uptake. HR = heart rate. LA = lactic acid. 
82 H.R. Scholte et al. / Biochimica et Biophysica Acta 1271 (1995) 75-83 
Table 5 
Plasma carnitine in patients and their family members 
Person Pedigree Carnitine ( p, mol/ l )  
Free Total 
CV a 11 24 
CV b 30;30 38;45 
Father 39 49 
Mother b 27 36 
Brother 21 28 
CB VI,2 34 40 
Father V, 1 38 44 
Mother V,2 29 34 
Sister VI, 1 24 31 
MJ VI,8 24 31 
JJ VI, 10 22;25 31 ;30 
Father V,3 47 52 
Mother V,4 34 40 
Sister VI,3 22 28 
Sister VI,5 29 32 
Sister VI,6 38 41 
Sister VI,9 28 35 
Sister VI, 11 26 36 
Controls (40) 40 51 
Controls range 26-58 31-74 
a Just after stopping carnitine supplementation. 
b Takes oral L-carnitine. 
nitinemic. All patients had healthy sib with low blood 
carnitine (Table 5). The question arises if this genetic 
background is required to get the mutation in the nuclear- 
encoded part of complex I. 
4. Discussion 
The clinical characteristics of these patients with ri- 
boflavin-responsive complex I deficiency were the follow- 
ing. The patients suffered from exercise intolerance by 
fatigue and pain. They had lactic acidosis, showed subsar- 
colemmal mitochondrial proliferation with increased activ- 
ities of the terminal respiratory chain. They had neither 
ragged-red fibres nor succinate-tetrazolium oxidoreductase 
or cytochrome c oxidase negative fibres. They had healthy 
siblings with low plasma carnitine. 
The increase of subsarcolemmal mitochondria n type I 
and in type II fibres in the patients is greater than that 
encountered in trained athletes. But the patients were of 
course not trained at all. This red but not ragged organiza- 
tion of the mitochondria s not pathological, in contrast to 
that in ragged-red fibres. In the former condition, mito- 
chondria ccumulate ata site where they are needed. In the 
ragged condition they accumulate also in the centre of the 
fibre and apparently at random, uncontrolled, no longer 
restrained by the cytoskeleton. It is tempting to speculate 
that the central localization of the mitochondria makes 
them more vulnerable to reactive oxygen species, because 
the proliferation of the mitochondria plus the defect in 
oxidative phosphorylation give rise to much more of these 
species than can be destroyed by the cellular protective 
mechanisms. Moreover these enzymatic and scavenging 
protection mechanisms may be much lower in the ragged- 
red fibres and/or less available. 
It is of interest hat the riboflavin therapy, albeit restor- 
ing the complex I activity to the lower normal range, did 
neither normalize blood lactate nor the proliferation of 
mitochondria. It is therefore likely that in vivo the activity 
is still too small. Kinetic measurements of complex I were 
not performed. 
It is fascinating that the activity of cytochrome c oxi- 
dase in the patients decreases with age. In the four biopsies 
the correlation coefficient between the enzyme activity and 
age, was found to be -0.94 (Table 3). 
In another wheel-chair bound patient, with lactic acido- 
sis, subsarcolemmal mitochondrial proliferation and defi- 
ciency of the adenine nucleotide translocator in muscle, we 
detected also such a decrease in cytochrome c oxidase 
with age [43]. At the age of 3.5 year his muscle had an 
activity of 176, expressed in the first order rate constant 
k.min-l.(g wet weight) -1, while at the age of 5.5 the 
activity was 115. In both biopsies, the other mitocbondrial 
enzyme activities were highly increased, and by immuno- 
blotting of the subunits of cytochrome c oxidase it became 
clear that the amount of protein of the subunits had also 
considerably increased. We attributed this paradoxal de- 
crease in cytochrome c oxidase activity to the generation 
of reactive oxygen species, peroxidizing the cardiolipin 
required for activity [44] and treated the patient with 1 g 
vitamin E per day. He improved within a short time, and 
no longer required his wheel- chair, except for long dis- 
tances [27]. Since blood lactate did not decline signifi- 
cantly, we concluded that the primary defect had not been 
cured. We interpreted the improvement following high 
vitamin E doses as a result of suppression of the genera- 
tion of reactive oxygen species caused by the mitochon- 
drial proliferation [28]. It will be clear that the patients of 
this communication are at present also treated with vitamin 
E, but exercise testing has not yet been performed. 
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